Ascendis Pharma (ASND) Tops Q4 EPS by 37c

Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR1.54), EUR0.37 better than the analyst estimate of (EUR1.91). Revenue for the quarter came in at EUR137.7 million versus the consensus estimate of EUR85.87 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group
• Pfizer reaffirms 2026 guidance after CFO transition news